MX368178B - Compuestos de ácido dimetilbenzoico. - Google Patents
Compuestos de ácido dimetilbenzoico.Info
- Publication number
- MX368178B MX368178B MX2016007861A MX2016007861A MX368178B MX 368178 B MX368178 B MX 368178B MX 2016007861 A MX2016007861 A MX 2016007861A MX 2016007861 A MX2016007861 A MX 2016007861A MX 368178 B MX368178 B MX 368178B
- Authority
- MX
- Mexico
- Prior art keywords
- acid compounds
- dimethylbenzoic acid
- dimethylbenzoic
- receptor
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
(ver Fórmula) La presente invención proporciona un compuesto de la fórmula I: en donde A es: y W, Y, X, R1, R2, R3 y R4 son como se definen en la presente, o una sal de éste aceptable desde el punto de vista farmacéutico, para uso como un inhibidor del receptor de EP4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361916824P | 2013-12-17 | 2013-12-17 | |
PCT/US2014/069783 WO2015094912A1 (en) | 2013-12-17 | 2014-12-11 | Dimethylbenzoic acid compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016007861A MX2016007861A (es) | 2017-01-11 |
MX368178B true MX368178B (es) | 2019-09-23 |
Family
ID=52355186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016007861A MX368178B (es) | 2013-12-17 | 2014-12-11 | Compuestos de ácido dimetilbenzoico. |
Country Status (23)
Country | Link |
---|---|
US (1) | US10005721B2 (es) |
EP (1) | EP3083554B1 (es) |
JP (1) | JP6200596B2 (es) |
KR (1) | KR101937186B1 (es) |
CN (1) | CN105793236B (es) |
AU (1) | AU2014366371B2 (es) |
CA (1) | CA2929562A1 (es) |
CY (1) | CY1121677T1 (es) |
DK (1) | DK3083554T3 (es) |
EA (1) | EA028675B1 (es) |
ES (1) | ES2727329T3 (es) |
HR (1) | HRP20190793T1 (es) |
HU (1) | HUE043614T2 (es) |
LT (1) | LT3083554T (es) |
ME (1) | ME03398B (es) |
MX (1) | MX368178B (es) |
PL (1) | PL3083554T3 (es) |
PT (1) | PT3083554T (es) |
RS (1) | RS58594B1 (es) |
SA (1) | SA516371324B1 (es) |
SI (1) | SI3083554T1 (es) |
TR (1) | TR201904327T4 (es) |
WO (1) | WO2015094912A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016037954A1 (de) * | 2014-09-09 | 2016-03-17 | Bayer Pharma Aktiengesellschaft | Substituierte n,2-diarylchinolin-4-carboxamide und ihre anti-inflammatorische verwendung |
US10745382B2 (en) * | 2015-10-15 | 2020-08-18 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
WO2017153235A1 (de) * | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung |
EP3609869A1 (de) | 2017-04-10 | 2020-02-19 | Bayer Aktiengesellschaft | Substituierte n-arylethyl-2-arylchinolin-4-carboxamide und ihre verwendung |
TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
ES2896476T3 (es) | 2017-05-18 | 2022-02-24 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina |
EA201992677A1 (ru) | 2017-05-18 | 2020-04-23 | Идорсия Фармасьютиклз Лтд | Пиримидиновые производные в качестве модуляторов pge2 рецепторов |
MX2019013718A (es) | 2017-05-18 | 2020-01-30 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2. |
AR111807A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2 |
MX2019013639A (es) | 2017-05-18 | 2020-01-21 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos. |
US20220064113A1 (en) * | 2019-01-22 | 2022-03-03 | Keythera (Suzhou) Pharmaceuticals Co. Ltd. | Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof |
WO2022102731A1 (ja) | 2020-11-13 | 2022-05-19 | 小野薬品工業株式会社 | Ep4拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1270615B (it) | 1994-07-14 | 1997-05-07 | Smithkline Beecham Farma | Uso di derivati di chinolina |
TW502026B (en) * | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
PL350448A1 (en) * | 1999-03-17 | 2002-12-16 | Astrazeneca Ab | Amide derivatives |
AU2004268839A1 (en) * | 2003-09-03 | 2005-03-10 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists |
WO2005030753A2 (en) | 2003-09-22 | 2005-04-07 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
GB0324269D0 (en) * | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
EP1723132A1 (en) * | 2004-02-12 | 2006-11-22 | Asterand Uk Limited | Ep2 receptor agonists |
AP2006003769A0 (en) * | 2004-05-04 | 2006-10-31 | Pfizer | Ortho substituted aryl or heteroaryl amide compounds |
US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
JP5183628B2 (ja) * | 2006-06-12 | 2013-04-17 | メルク カナダ インコーポレイテッド | Ep4受容体リガンドとしてのインドリンアミド誘導体 |
WO2009005076A1 (ja) * | 2007-07-03 | 2009-01-08 | Astellas Pharma Inc. | アミド化合物 |
WO2010043592A1 (en) | 2008-10-15 | 2010-04-22 | Revotar Biopharmaceuticals Ag | Lipase inhibitors for use for the treatment of obesity |
RU2529860C2 (ru) * | 2009-01-30 | 2014-10-10 | Тояма Кемикал Ко., Лтд. | Производное n-ацилантраниловой кислоты или его соль |
AU2010231058A1 (en) * | 2009-03-31 | 2011-11-10 | Renascience Co., Ltd. | Plasminogen activator inhibitor-1 inhibitor |
WO2012004293A2 (de) | 2010-07-08 | 2012-01-12 | Bayer Cropscience Ag | Insektizide und fungizide wirkstoffkombinationen |
WO2012117097A1 (en) | 2011-03-03 | 2012-09-07 | Universität des Saarlandes | Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors |
CN103874682A (zh) * | 2011-08-31 | 2014-06-18 | 阿玛克姆股份有限公司 | 作为rock激酶抑制剂的联苯基羧酰胺 |
US9249085B2 (en) * | 2011-09-16 | 2016-02-02 | Fovea Pharmaceuticals | Aniline derivatives, their preparation and their therapeutic application |
TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基-苯甲酸化合物 |
EP2765128A1 (en) * | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
-
2014
- 2014-12-11 JP JP2016538636A patent/JP6200596B2/ja not_active Expired - Fee Related
- 2014-12-11 WO PCT/US2014/069783 patent/WO2015094912A1/en active Application Filing
- 2014-12-11 KR KR1020167015772A patent/KR101937186B1/ko active IP Right Grant
- 2014-12-11 ME MEP-2019-106A patent/ME03398B/me unknown
- 2014-12-11 EP EP14827908.6A patent/EP3083554B1/en active Active
- 2014-12-11 HU HUE14827908A patent/HUE043614T2/hu unknown
- 2014-12-11 PL PL14827908T patent/PL3083554T3/pl unknown
- 2014-12-11 MX MX2016007861A patent/MX368178B/es active IP Right Grant
- 2014-12-11 SI SI201431139T patent/SI3083554T1/sl unknown
- 2014-12-11 EA EA201690911A patent/EA028675B1/ru not_active IP Right Cessation
- 2014-12-11 CN CN201480066576.6A patent/CN105793236B/zh not_active Expired - Fee Related
- 2014-12-11 ES ES14827908T patent/ES2727329T3/es active Active
- 2014-12-11 CA CA2929562A patent/CA2929562A1/en not_active Abandoned
- 2014-12-11 AU AU2014366371A patent/AU2014366371B2/en not_active Ceased
- 2014-12-11 RS RS20190469A patent/RS58594B1/sr unknown
- 2014-12-11 US US15/030,891 patent/US10005721B2/en not_active Expired - Fee Related
- 2014-12-11 TR TR2019/04327T patent/TR201904327T4/tr unknown
- 2014-12-11 PT PT14827908T patent/PT3083554T/pt unknown
- 2014-12-11 LT LTEP14827908.6T patent/LT3083554T/lt unknown
- 2014-12-11 DK DK14827908.6T patent/DK3083554T3/da active
-
2016
- 2016-06-14 SA SA516371324A patent/SA516371324B1/ar unknown
-
2019
- 2019-04-29 HR HRP20190793TT patent/HRP20190793T1/hr unknown
- 2019-05-08 CY CY20191100495T patent/CY1121677T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP6200596B2 (ja) | 2017-09-20 |
LT3083554T (lt) | 2019-05-10 |
CA2929562A1 (en) | 2015-06-25 |
EP3083554A1 (en) | 2016-10-26 |
WO2015094912A1 (en) | 2015-06-25 |
TR201904327T4 (tr) | 2019-04-22 |
DK3083554T3 (da) | 2019-05-13 |
PT3083554T (pt) | 2019-06-11 |
MX2016007861A (es) | 2017-01-11 |
JP2017500309A (ja) | 2017-01-05 |
RS58594B1 (sr) | 2019-05-31 |
HRP20190793T1 (hr) | 2019-06-28 |
HUE043614T2 (hu) | 2019-08-28 |
US10005721B2 (en) | 2018-06-26 |
KR20160086905A (ko) | 2016-07-20 |
AU2014366371A1 (en) | 2016-05-19 |
KR101937186B1 (ko) | 2019-01-10 |
EA201690911A1 (ru) | 2016-09-30 |
SI3083554T1 (sl) | 2019-04-30 |
EP3083554B1 (en) | 2019-03-13 |
ES2727329T3 (es) | 2019-10-15 |
CN105793236A (zh) | 2016-07-20 |
ME03398B (me) | 2020-01-20 |
SA516371324B1 (ar) | 2018-03-22 |
CY1121677T1 (el) | 2020-07-31 |
EA028675B1 (ru) | 2017-12-29 |
CN105793236B (zh) | 2017-10-10 |
US20160251306A1 (en) | 2016-09-01 |
PL3083554T3 (pl) | 2019-08-30 |
AU2014366371B2 (en) | 2017-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX368178B (es) | Compuestos de ácido dimetilbenzoico. | |
PH12015502232A1 (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
PH12015502031A1 (en) | Tetrahydropyrrolothiazine compounds | |
RS54730B1 (sr) | Inhibitori beta sekretaze | |
JO3318B1 (ar) | مثبطات bace | |
MY176803A (en) | Polymorph of syk inhibitors | |
RS54526B1 (en) | USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS | |
EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
PH12015500009B1 (en) | Phenoxyethyl piperidine compounds | |
UA113086C2 (xx) | Піразольні сполуки як інгібітори sglt1 | |
MX2015015841A (es) | Compuestos de fenoxietil dihidro-1h-isoquinolina. | |
NZ725165A (en) | Analogues of 4h-pyrazolo[1,5-α]benzimidazole compound as parp inhibitors | |
MX2016007985A (es) | Compuestos de fluorofenilpirazol. | |
MX359399B (es) | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. | |
MX2016006667A (es) | Derivados de pirrolo-pirrolona y su uso como inhibidores. | |
PH12015502462A1 (en) | Imidazo-triazine derivatives as pde10 inhibitors | |
EA201690593A1 (ru) | Новые соединения мочевины |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |